H.C. Wainwright raised the firm’s price target on Tourmaline Bio (TRML) to $50 from $49 and keeps a Buy rating on the shares following the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio’s 2024 Financial Results and Strategic Advances
- Tourmaline Bio: Strong Financials and Promising Pipeline Drive Buy Rating
- Tourmaline Bio reports Q4 EPS (86c), consensus (87c)
- Tourmaline Bio sees cash runway into 2H27
- Robinhood initiated, MongoDB downgraded: Wall Street’s top analyst calls